Infectious Diseases Physician Dr Bernard Hudson discusses the burden of dengue disease and the role of a vaccine in dengue prevention.
In this Product Explainer:
Infectious Diseases Physician Dr Bernard Hudson discusses the burden of dengue disease, the role of Qdenga in dengue prevention, key clinical considerations, and practical insights for healthcare professionals (6 mins).
This video was produced with funding from Takeda
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events to the TGA here.
PBS Information: This product is not listed on the National Immunisation Program (NIP) or the PBS.
For healthcare professionals only. Please review Product Information before prescribing. The full Product Information for QDENGA® DENGUE TETRAVALENT VACCINE (LIVE, ATTENUATED) can be accessed here.
QDENGA® is a registered trademark of Takeda Vaccines, Inc. TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda Pharmaceutical Company Limited. Takeda Pharmaceuticals Australia Pty Limited, Sydney NSW 2000. ABN 71 095 610 870. Telephone: 1800 012 612. C-APROM/AU/QDE/0026. Date of Preparation: September 2026
